Nuvation Bio/$NUVB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Ticker
$NUVB
Sector
Primary listing
NYSE
Employees
307
Headquarters
Website
Nuvation Bio Metrics
BasicAdvanced
$1.7bn
-
-$0.42
1.52
-
Price and volume
Market cap
$1.7bn
Beta
1.52
52-week high
$9.75
52-week low
$1.57
Average daily volume
4.3m
Financial strength
Current ratio
7.439
Quick ratio
7.038
Long term debt to equity
63.027
Total debt to equity
67.9
Interest coverage (TTM)
-7.38%
Profitability
EBITDA (TTM)
-148.214
Gross margin (TTM)
90.78%
Net profit margin (TTM)
-102.06%
Operating margin (TTM)
-104.99%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-17.02%
Return on equity (TTM)
-39.51%
Valuation
Price to revenue (TTM)
11.414
Price to book
5.17
Price to tangible book (TTM)
5.35
Price to free cash flow (TTM)
-12.179
Free cash flow yield (TTM)
-8.21%
Free cash flow per share (TTM)
-0.39
Growth
Revenue change (TTM)
1,205.52%
Earnings per share change (TTM)
-79.09%
3-year earnings per share growth (CAGR)
-3.98%
What the Analysts think about Nuvation Bio
Analyst ratings (Buy, Hold, Sell) for Nuvation Bio stock.
Nuvation Bio Financial Performance
Revenues and expenses
Nuvation Bio Earnings Performance
Company profitability
Nuvation Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs